Loading...
•
Mar 31, 2025
PROCEPT BioRobotics Q1 2025 Earnings Report
PROCEPT BioRobotics reported a 55% year-over-year revenue increase and narrowed its net loss in the first quarter of 2025.
Key Takeaways
The company saw strong revenue growth driven by U.S. handpiece sales and international expansion. While it remained unprofitable, it reduced its net loss and showed positive momentum with its Hydros™ system adoption among large health networks.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
PROCEPT raised its full-year revenue guidance and reaffirmed expected operating expenses and EBITDA losses.
Positive Outlook
- Increased full-year revenue guidance to $323M
- Expected gross margin of 64.5% for full year
- Strong growth in U.S. IDN orders
- Hydros™ launch building momentum
- Procedural growth expected to remain strong
Challenges Ahead
- Projected full-year net loss of $82.4M
- Adjusted EBITDA loss forecast of $35M
- Potential gross margin headwind from global tariffs (~$5M impact)
- Majority of tariff impact expected in H2 2025
- Operating expenses projected at $300M for the year
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...